Cell-free immuno-profiling on a genetically programmed biochip
Source abstract
Abstract
Cell-free synthetic biology approaches offer biosafe, low-cost and versatile genetic tools to advance therapeutic research and development. Measuring the antibody response to a range of target and off-target proteins is essential for deep immuno-profiling of therapeutic antibodies and individual patient immune responses. Here we extend a previously developed microfluidic-free biochip platform to quantitatively reconstitute interactions of cell-free synthesized antigens with antibodies in miniaturized, photolithographically patterned compartments from localized gene brushes. This creates a continuous density gradient of antigens displayed on the surface, generating multiple antibody binding curves, one in each single nanolitre-volume compartment for affinity determination. We used SARS-CoV-2 antigens to profile the specificity and affinity of monoclonal antibodies to more than 30 viral epitopes, which were synthesized simultaneously on a single chip. We also profiled polyclonal antibodies in a total of 1 μl of human serum, revealing patient-specific epitope profiles that are difficult to detect by conventional approaches. By spatially separating gene brushes in the compartment, we extended the gradient approach to reconstitute the interaction of on-chip cell-free expressed human ACE2 receptor with the viral receptor-binding domain in a specific manner. This on-chip genetically programmed approach enables rapid and quantitative interrogation of complex protein-protein interactions, without protein purification steps, for human immuno-profiling and preparedness for emerging pathogens.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Biosensing Techniques and Applications · Microfluidic and Bio-sensing Technologies · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Yuan, J. et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J. Immunother. Cancer 4, 3 (2016).10.1186/s40425-016-0107-3 ↗
2. Connors, J. et al. Using the power of innate immunoprofiling to understand vaccine design, infection, and immunity. Hum. Vaccines Immunother. 19, 2267295 (2023).10.1080/21645515.2023.2267295 ↗
3. Ogunniyi, A. O. et al. Profiling human antibody responses by integrated single-cell analysis. Vaccine 32, 2866–2873 (2014).10.1016/j.vaccine.2014.02.020 ↗
4. Stork, E. M. et al. Antigen-specific Fab profiling achieves molecular-resolution analysis of human autoantibody repertoires in rheumatoid arthritis. Nat. Commun. 15, 3114 (2024).10.1038/s41467-024-47337-x ↗
5. Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).10.1186/s12929-019-0592-z ↗
6. Deshaies, R. J. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature 580, 329–338 (2020).10.1038/s41586-020-2168-1 ↗
7. Zhong, X., D’antona, A. M., Karagiannis, S. & White, A. Recent advances in the molecular design and applications of multispecific biotherapeutics. Antibodies 10, 13 (2021).10.3390/antib10020013 ↗
8. Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361–370 (2015).10.1038/nrc3930 ↗
9. Gérard, A. et al. High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nat. Biotechnol. 38, 715–721 (2020).10.1038/s41587-020-0466-7 ↗
10. Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).10.1038/s41467-020-17892-0 ↗
11. Tickle, S. et al. High-throughput screening for high affinity antibodies. J. Lab. Autom. 14, 303–307 (2009).10.1016/j.jala.2009.05.004 ↗
12. Schofield, D. J. et al. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 8, R254 (2007).10.1186/gb-2007-8-11-r254 ↗
13. Carlson, E. D., Gan, R., Hodgman, C. E. & Jewett, M. C. Cell-free protein synthesis: applications come of age. Biotechnol. Adv. 30, 1185–1194 (2012).10.1016/j.biotechadv.2011.09.016 ↗
14. Cubillos-Ruiz, A. et al. Engineering living therapeutics with synthetic biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).10.1038/s41573-021-00285-3 ↗
15. Gu, Y. et al. Cell-free protein synthesis system for bioanalysis: advances in methods and applications. Trends Anal. Chem. 161, 117015 (2023).10.1016/j.trac.2023.117015 ↗
16. Slomovic, S., Pardee, K. & Collins, J. J. Synthetic biology devices for in vitro and in vivo diagnostics. Proc. Natl Acad. Sci. USA 112, 14429–14435 (2015).10.1073/pnas.1508521112 ↗
17. Murray, C. J. & Baliga, R. Cell-free translation of peptides and proteins:from high throughput screening to clinical production. Curr. Opin. Chem. Biol. 17, 420–426 (2013).10.1016/j.cbpa.2013.02.014 ↗
18. Ramm, F. et al. Mammalian cell-free protein expression promotes the functional characterization of the tripartite non-hemolytic enterotoxin from Bacillus cereus. Sci. Rep. 10, 2887 (2020).10.1038/s41598-020-59634-8 ↗
19. Thoring, L. et al. Cell-free systems based on CHO cell lysates: optimization strategies, synthesis of “difficult-to-express” proteins and future perspectives. PLoS ONE 11, e0163670 (2016).10.1371/journal.pone.0163670 ↗
20. Garenne, D., Bowden, S. & Noireaux, V. Cell-free expression and synthesis of viruses and bacteriophages: applications to medicine and nanotechnology. Curr. Opin. Syst. Biol. 28, 100373 (2021).10.1016/j.coisb.2021.100373 ↗
21. Sullivan, C. J. et al. A cell-free expression and purification process for rapid production of protein biologics. Biotechnol. J. 11, 238–248 (2016).10.1002/biot.201500214 ↗
22. Pardee, K. et al. Rapid, low-cost detection of Zika virus using programmable biomolecular components. Cell 165, 1255–1266 (2016).10.1016/j.cell.2016.04.059 ↗
23. Silverman, A. D., Akova, U., Alam, K. K., Jewett, M. C. & Lucks, J. B. Design and optimization of a cell-free atrazine biosensor. ACS Synth. Biol. 9, 671–677 (2020).10.1021/acssynbio.9b00388 ↗
24. Wen, K. Y. et al. A cell-free biosensor for detecting quorum sensing molecules in P. aeruginosa-infected respiratory samples. ACS Synth. Biol. 6, 2293–2301 (2017).10.1021/acssynbio.7b00219 ↗
25. Hunt, A. C. et al. A rapid cell-free expression and screening platform for antibody discovery. Nat. Commun. 14, 3897 (2023).10.1038/s41467-023-38965-w ↗
26. Ojima-Kato, T., Nagai, S. & Nakano, H. Ecobody technology: rapid monoclonal antibody screening method from single B cells using cell-free protein synthesis for antigen-binding fragment formation. Sci. Rep. 7, 13979 (2017).10.1038/s41598-017-14277-0 ↗
27. Stech, M. & Kubick, S. Cell-free synthesis meets antibody production: a review. Antibodies 4, 12–33 (2015).10.3390/antib4010012 ↗
28. Ramachandran, N. et al. Self-assembling protein microarrays. Science 305, 86–90 (2004).10.1126/science.1097639 ↗
29. Gerber, D., Maerkl, S. J. & Quake, S. R. An in vitro microfluidic approach to generating protein-interaction networks. Nat. Methods 6, 71–74 (2009).10.1038/nmeth.1289 ↗
30. Blackburn, M. C., Petrova, E., Correia, B. E. & Maerkl, S. J. Integrating gene synthesis and microfluidic protein analysis for rapid protein engineering. Nucleic Acids Res. 44, e68 (2015).10.1093/nar/gkv1497 ↗
31. Markin, C. J. et al. Revealing enzyme functional architecture via high-throughput microfluidic enzyme kinetics. Science 373, eabf8761 (2021).10.1126/science.abf8761 ↗
32. Norouzi, M. et al. Cell-free dot blot: an ultra-low-cost and practical immunoassay platform for detection of anti-SARS-CoV-2 antibodies in human and animal sera. Microbiol. Spectr. 11, e0245722 (2023).10.1128/spectrum.02457-22 ↗
33. Hufnagel, K. et al. In situ, cell-free protein expression on microarrays and their use for the detection of immune responses. Bio-protocol 9, e3152 (2019).10.21769/BioProtoc.3152 ↗
34. Goshima, N. et al. Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat. Methods 5, 1011–1017 (2008).10.1038/nmeth.1273 ↗
35. Morishita, R. et al. CF-PA2Vtech: a cell-free human protein array technology for antibody validation against human proteins. Sci. Rep. 9, 19349 (2019).10.1038/s41598-019-55785-5 ↗
36. Levy, M., Falkovich, R., Daube, S. S. & Bar-Ziv, R. H. Autonomous synthesis and assembly of a ribosomal subunit on a chip. Sci. Adv. 6, eaaz6020 (2020).10.1126/sciadv.aaz6020 ↗
37. Vonshak, O. et al. Programming multi-protein assembly by gene-brush patterns and two-dimensional compartment geometry. Nat. Nanotechnol. 15, 783–791 (2020).10.1038/s41565-020-0720-7 ↗
38. Buxboim, A. et al. A single-step photolithographic interface for cell-free gene expression and active biochips. Small 3, 500–510 (2007).10.1002/smll.200600489 ↗
39. Bracha, D. et al. Entropy-driven collective interactions in DNA brushes on a biochip. Proc. Natl Acad. Sci. USA 110, 4534–4538 (2013).10.1073/pnas.1220076110 ↗
40. Förste, S. et al. Computational analysis of protein synthesis, diffusion, and binding in compartmental biochips. Microb. Cell Fact. 22, 244 (2023).10.1186/s12934-023-02237-5 ↗
41. Buxboim, A., Daube, S. S. & Bar-Ziv, R. Synthetic gene brushes: a structure–function relationship. Mol. Syst. Biol. 4, 181 (2008).10.1038/msb.2008.20 ↗
42. Caschera, F. & Noireaux, V. Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription–translation system. Biochimie 99, 162–168 (2014).10.1016/j.biochi.2013.11.025 ↗
43. Zhang, S., Garcia-D’Angeli, A., Brennan, J. P. & Huo, Q. Predicting detection limits of enzyme-linked immunosorbent assay (ELISA) and bioanalytical techniques in general. Analyst 139, 439–445 (2013).10.1039/C3AN01835K ↗
44. Seydoux, E. et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 53, 98–105.e5 (2020).10.1016/j.immuni.2020.06.001 ↗
45. Ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 3, 1071–1079 (2006).10.1371/journal.pmed.0030237 ↗
46. Gong, Y., Qin, S. & Dai, L. The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduct. Target. Ther. 6, 396 (2021).10.1038/s41392-021-00809-8 ↗
47. Telenti, A., Hodcroft, E. B. & Robertson, D. L. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb. Perspect. Med. 12, a041390 (2022).10.1101/cshperspect.a041390 ↗
48. Huang, M. et al. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape. Immunity 55, 1501–1514 (2022).10.1016/j.immuni.2022.06.005 ↗
49. Lee, C. H. et al. Potential CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains. Front. Immunol. 11, 579480 (2020).10.3389/fimmu.2020.579480 ↗
50. Wu, W., Cheng, Y., Zhou, H., Sun, C. & Zhang, S. The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol. J. 20, 6 (2023).10.1186/s12985-023-01968-6 ↗
51. Movsisyan, M. et al. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection. Sci. Rep. 14, 13417 (2024).10.1038/s41598-024-64414-9 ↗
52. Kightlinger, W. et al. A cell-free biosynthesis platform for modular construction of protein glycosylation pathways. Nat. Commun. 10, 5404 (2019).10.1038/s41467-019-12024-9 ↗
53. Marani, M., Katul, G. G., Pan, W. K. & Parolari, A. J. Intensity and frequency of extreme novel epidemics. Proc. Natl Acad. Sci. USA 118, e2105482118 (2021).10.1073/pnas.2105482118 ↗
54. Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat. Commun. 11, 5413 (2020).10.1038/s41467-020-19231-9 ↗
55. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).10.1038/nmeth.1318 ↗
56. Buxboim, A., Daube, S. S. & Bar-Ziv, R. Ultradense synthetic gene brushes on a chip. Nano Lett. 9, 909–913 (2009).10.1021/nl8039124 ↗
57. Garamella, J., Marshall, R., Rustad, M. & Noireaux, V. The all E. coli TX-TL Toolbox 2.0: a platform for cell-free synthetic biology. ACS Synth. Biol. 5, 344–355 (2016).10.1021/acssynbio.5b00296 ↗
58. He, B. et al. Rapid mutagenesis and purification of phage RNA polymerases. Protein Expr. Purif. 9, 142–151 (1997).10.1006/prep.1996.0663 ↗
59. Yu, T., Laird, J. R., Prescher, J. A. & Thorpe, C. Gaussia princeps luciferase: a bioluminescent substrate for oxidative protein folding. Protein Sci. 27, 1509–1517 (2018).10.1002/pro.3433 ↗
60. Dupin, A. Cell-free immuno-profiling on a genetically programmed biochip. Zenodo https://doi.org/10.5281/zenodo.17151196 (2025).10.5281/zenodo.17151196 ↗